治疗眼疾的突破
由三名科大生物材料研究员组成的研究团队开发全球首创的可注射凝胶，使蛋白质药物缓慢释放，预期可用于治疗眼疾如黄斑病变及糖尿眼。现今，这些病患者多年来需要接受每月的药物注射，治疗方案并不理想。
团队成员及科大生物医学工程学部博士研究员余渝表示︰「药物经配制成可注射凝胶后会慢慢释放药力，可能成为一项有效而且药效持久的治疗。」
生物医学工程学部副教授周迎指出病人只需每年注射一次可注射凝胶，而无需承受每月注射的痛苦。同时，这项创新技术有助减低医疗开支及持续注射的风险。
展望将来，研究团队将于三至四年内展开人体临床实验。长远而言，队伍希望这项治疗技术可应用于中国及其他贫困地区，帮助有需要的病人获得廉价和有效的治疗。
这项崭新突破令研究团队成立的公司NovaMatrix Ltd.在科大第五届100万元创业计划中夺得季军。这项年度计划旨在推动创业文化及发掘拥有最佳商业前景的方案。
About The Hong Kong University of Science and Technology
The Hong Kong University of Science and Technology (HKUST) (www.ust.hk) is a world-class research university that focuses on science, technology and business as well as humanities and social science. HKUST offers an international campus, and a holistic and interdisciplinary pedagogy to nurture well-rounded graduates with global vision, a strong entrepreneurial spirit and innovative thinking. HKUST attained the highest proportion of internationally excellent research work in the Research Assessment Exercise 2014 of Hong Kong’s University Grants Committee, and is ranked as the world’s best young university in Times Higher Education’s Young University Rankings 2019. Its graduates were ranked 16th worldwide and top in Greater China in Global University Employability Survey 2018.
